Healthy Clinical Trial
Official title:
The Effect of High-definition Transcranial Direct Current Stimulation of the Somatosensory Area on Upper Limb Motor Performance in Healthy Adults
Verified date | January 2021 |
Source | Ariel University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
to investigate the effect of transcranial direct current stimulation of the somatosensory area on upper limb motor performance in healthy adults
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | April 1, 2022 |
Est. primary completion date | January 7, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 35 Years |
Eligibility | Inclusion Criteria: - aged between 20 and 35 - right-hand dominant - healthy according to self report Exclusion Criteria: - taking psychiatric medications - a history of drug / alcohol abuse or dependence - psychiatric or neurological disorder - a history of seizures - metal implants in their head - musculoskeletal deficits interfering with task performance (proper reaching performance in sitting) |
Country | Name | City | State |
---|---|---|---|
Israel | Ariel University | Ariel |
Lead Sponsor | Collaborator |
---|---|
Ariel University | Tel Aviv University |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in movement time (s) from baseline to intervention | Time from movement onset (first time the tangential velocity was greater than 5% of the peak tangential velocity) until the end of the movement (the last time the tangential velocity will be greater than 5% of the peak tangential velocity). Improved motor performance will be indicated by a shorter movement time. | Baseline (immediately before stimulation), two minutes after starting the stimulation | |
Primary | Change in movement time (s) from baseline to posttest | Time from movement onset (first time the tangential velocity was greater than 5% of the peak tangential velocity) until the end of the movement (the last time the tangential velocity will be greater than 5% of the peak tangential velocity). Improved motor performance will be indicated by a shorter movement time. | Baseline (immediately before stimulation), immediately post stimulation | |
Primary | Change in movement time (s) from intervention to posttest | Time from movement onset (first time the tangential velocity was greater than 5% of the peak tangential velocity) until the end of the movement (the last time the tangential velocity will be greater than 5% of the peak tangential velocity). Improved motor performance will be indicated by a shorter movement time. | Two minutes after starting the stimulation, immediately post stimulation | |
Primary | Change in reaction time (s) from baseline to intervention | Time between when the target appeared in green (changed color from white to green), and movement onset. Improved motor performance will be indicated by a shorter reaction time. | Baseline (immediately before stimulation), two minutes after starting the stimulation | |
Primary | Change in reaction time (s) from baseline to posttest | Time between when the target appeared in green (changed color from white to green), and movement onset. Improved motor performance will be indicated by a shorter reaction time. | Baseline (immediately before stimulation), immediately post stimulation | |
Primary | Change in reaction time (s) from intervention to posttest | Time between when the target appeared in green (changed color from white to green), and movement onset. Improved motor performance will be indicated by a shorter reaction time. | Two minutes after starting the stimulation, immediately post stimulation | |
Primary | Change in straight line deviation (cm) from baseline to intervention | Path deviation from a straight line (zero means no deviation). Improved motor performance will be indicated by a shorter deviation. | Baseline (immediately before stimulation), two minutes after starting the stimulation | |
Primary | Change in straight line deviation (cm) from baseline to posttest | Path deviation from a straight line (zero means no deviation). Improved motor performance will be indicated by a shorter deviation. | Baseline (immediately before stimulation), immediately post stimulation | |
Primary | Change in straight line deviation (cm) from intervention to posttest | Path deviation from a straight line (zero means no deviation). Improved motor performance will be indicated by a shorter deviation. | Two minutes after starting the stimulation, immediately post stimulation | |
Secondary | Change in the correct answers (%) of discriminative task from baseline to posttest | Identification of the orientation of the stimulus. Improved sensation will be indicated by a higher % of correct answers. | Baseline (immediately before stimulation), immediately after the motor posttest | |
Secondary | Change in end point error (cm) of proprioception task from baseline to posttest | The distance between the target point to the actual arrival location. Improved sensation will be indicated by a smaller distance. | Baseline (immediately before stimulation), immediately after the motor posttest |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |